Vericiguat- (VERIQUVO)-(Jan -2021)- To treat chronic Heart Failure
Drug Name:
Vericiguat- (VERIQUVO)-(Jan -2021)- To treat chronic Heart Failure
List Of Brands:
Indication Type Description:
Drug Interaction:
DRUG INTERACTIONS-(summary)
1. Other Soluble Guanylate Cyclase Stimulators- VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators [see Contraindications (4)].
2. PDE-5 Inhibitors - Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended because of the potential for hypotension
Indication:
U.S. FDA APPROVED DRUGS SURING 2021
Serial No 1
Name of the Drug- VERGUVO
Active Ingredient - Vericiguat
Pharmacological Classification- To treat chronic heart failure
Date of Approval- 1/19/2021
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use VERQUVO safely and effectively. See full prescribing information for VERQUVO. VERQUVOTM (vericiguat) tablets, for oral use
Initial U.S. Approval: 2021
WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning
* Do not administer VERQUVO to a pregnant female because it may cause fetal harm.
* Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment.
INDICATIONS AND USAGE
VERQUVO is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
DOSAGE AND ADMINISTRATION
*The recommended starting dose of VERQUVO is 2.5 mg orally once daily with food.
* Double the dose of VERQUVO approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.
Adverse Reaction:
ADVERSE REACTIONS
Most common adverse reactions reported in =5% are hypotension and anemia.
Contra-Indications:
CONTRAINDICATION
Patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators. Pregnancy
CONTRAINDICATION
Patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators. Pregnancy